{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:58:20Z","timestamp":1793321900981,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018688","name":"Symphogen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018688","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.esmoop.2021.100136","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T10:21:33Z","timestamp":1619518893000},"page":"100136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["How we treat locoregional melanoma"],"prefix":"10.1016","volume":"6","author":[{"given":"T.","family":"Troiani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"De Falco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Trojaniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100136_bib1","series-title":"Cutaneous Melanoma: Etiology and Therapy","article-title":"Epidemiology of melanoma","author":"Matthews","year":"2020"},{"key":"10.1016\/j.esmoop.2021.100136_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920925219","article-title":"Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations","volume":"12","author":"Giunta","year":"2020","journal-title":"Ther Adv Med Oncol."},{"key":"10.1016\/j.esmoop.2021.100136_bib3","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1093\/annonc\/mdz411","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Michielin","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100136_bib4","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.esmoop.2021.100136_bib5","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.19.01902","article-title":"Factors affecting sentinel node metastasis in thin (T1) cutaneous melanomas: development and external validation of a predictive nomogram","volume":"38","author":"Maurichi","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2021.100136_bib6","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N\u00a0Engl J Med."},{"key":"10.1016\/j.esmoop.2021.100136_bib7","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.18.02306","article-title":"Final analysis of DeCOG-SLT trial: no survival benefit for complete lymph node dissection in patients with melanoma with positive sentinel node","volume":"37","author":"Leiter","year":"2019","journal-title":"J\u00a0Clin Oncol."},{"key":"10.1016\/j.esmoop.2021.100136_bib8","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.annonc.2020.07.005","article-title":"ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee","volume":"31","author":"Michielin","year":"2020","journal-title":"Ann Oncol."},{"key":"10.1016\/j.esmoop.2021.100136_bib9","doi-asserted-by":"crossref","first-page":"7081","DOI":"10.2147\/OTT.S115245","article-title":"Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB\/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial","volume":"9","author":"Harrington","year":"2016","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.esmoop.2021.100136_bib10","doi-asserted-by":"crossref","first-page":"v903","DOI":"10.1093\/annonc\/mdz394.063","volume":"30","author":"Dummer","year":"2019","journal-title":"Ann Oncol."},{"key":"10.1016\/j.esmoop.2021.100136_bib11","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1002\/jso.24921","article-title":"Intralesional PV-10 for the treatment of in-transit melanoma metastases \u2013 results of a prospective, non-randomized, single center study","volume":"117","author":"Read","year":"2018","journal-title":"J\u00a0Surg Oncol."},{"key":"10.1016\/j.esmoop.2021.100136_bib12","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1245\/s10434-016-5150-2","article-title":"Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma","volume":"23","author":"Dossett","year":"2016","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.esmoop.2021.100136_bib13","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejso.2016.10.005","article-title":"Diagnosis and treatment of in-transit melanoma metastases","volume":"43","author":"Testori","year":"2017","journal-title":"Eur J Surg Oncol."},{"key":"10.1016\/j.esmoop.2021.100136_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejca.2017.06.006","article-title":"Adjuvant interferon-\u03b1 for the treatment of high-risk melanoma: an individual patient data meta-analysis","volume":"82","author":"Ives","year":"2017","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.esmoop.2021.100136_bib15","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.esmoop.2021.100136_bib16","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med."},{"key":"10.1016\/j.esmoop.2021.100136_bib17","doi-asserted-by":"crossref","first-page":"S731","DOI":"10.1016\/j.annonc.2020.08.1200","article-title":"1076O Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III\/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238","volume":"31","author":"Weber","year":"2020","journal-title":"Ann Oncol."},{"key":"10.1016\/j.esmoop.2021.100136_bib18","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N\u00a0Engl J Med."},{"key":"10.1016\/j.esmoop.2021.100136_bib19","doi-asserted-by":"crossref","first-page":"S1175","DOI":"10.1016\/j.annonc.2020.08.2276","article-title":"LBA46 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: final results regarding distant metastasis-free survival from the EORTC 1325-MG\/Keynote 054 double-blinded phase III trial","volume":"31","author":"Eggermont","year":"2020","journal-title":"Ann Oncol."},{"key":"10.1016\/j.esmoop.2021.100136_bib20","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N\u00a0Engl J Med."},{"key":"10.1016\/j.esmoop.2021.100136_bib21","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1200\/JCO.2020.38.15_suppl.10001","article-title":"Long-term benefit of adjuvant dabrafenib\u00a0+ trametinib (D+T) in patients (pts) with resected stage III BRAF V600\u2013mutant melanoma: five-year analysis of COMBI-AD","volume":"38","author":"Hauschild","year":"2020","journal-title":"J\u00a0Clin Oncol."},{"key":"10.1016\/j.esmoop.2021.100136_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2013.08.023","article-title":"The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients","volume":"50","author":"van der Ploeg","year":"2014","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.esmoop.2021.100136_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ctrv.2018.06.003","article-title":"It is finally time for adjuvant therapy in melanoma","volume":"69","author":"Napolitano","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2021.100136_bib24","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.1200\/JCO.2020.38.15_suppl.10016","article-title":"Melanoma recurrence after adjuvant targeted therapy: a multicenter analysis","volume":"38","author":"Bhave","year":"2020","journal-title":"J\u00a0Clin Oncol."},{"key":"10.1016\/j.esmoop.2021.100136_bib25","article-title":"L3 update of the OpACIN and OpACIN-neo trials: 36-months and 24-months relapse-free survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma patients","volume":"8","author":"Versluis","year":"2020","journal-title":"J\u00a0Immunother Cancer."},{"key":"10.1016\/j.esmoop.2021.100136_bib26","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB\u2013C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.esmoop.2021.100136_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med."}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:27:11Z","timestamp":1761856031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921000958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2059702921000958"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100136","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How we treat locoregional melanoma","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100136"}}